Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

被引：0
|
作者：
Karly P. Garnock-Jones
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs & Aging | 2011年 / 28卷
关键词：
Atrial Fibrillation; Warfarin; Dabigatran; Major Bleeding; Haemorrhagic Stroke;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The need for safe, effective and easily administered and monitored anti-thrombotic treatments that do not have the issues common to warfarin treatment has led to the development of new anticoagulant drugs. Dabigatran etexilate (Pradaxa®, Pradax™) is a prodrug of the direct thrombin inhibitor dabigatran, a direct, reversible, potent inhibitor of thrombin. Dabigatran does not interact with food, and is associated with very few known drug interactions.
引用
收藏
页码：415 / 419
页数：4
相关论文
共 50 条
  • [1] Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
    Garnock-Jones, Karly P.
    [J]. DRUGS & AGING, 2011, 28 (05) : 415 - 419
  • [2] Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance
    Ahmad, Yousif
    Lip, Gregory Y. H.
    [J]. HEART, 2012, 98 (19) : 1404 - 1406
  • [3] Dabigatran Etexilate A Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
    Garnock-Jones, Karly P.
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2011, 11 (01) : 57 - 72
  • [4] Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
    Kansal, Anuraag R.
    Sorensen, Sonja V.
    Gani, Ray
    Robinson, Paul
    Pan, Feng
    Plumb, Jonathan M.
    Cowie, Martin R.
    [J]. HEART, 2012, 98 (07) : 573 - 578
  • [5] Dabigatran Etexilate A Pharmacoeconomic Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
    McKeage, Kate
    [J]. PHARMACOECONOMICS, 2012, 30 (09) : 841 - 855
  • [6] Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
    Chang, Chia-Hsien
    Yang, Yea-Huei Kao
    Chen, Jyh-Hong
    Lin, Li-Jen
    [J]. THROMBOSIS RESEARCH, 2014, 133 (05) : 782 - 789
  • [7] COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE COMPARED TO RIVAROXABAN FOR PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION IN CHINA
    Dong, S.
    Wu, B.
    Zhai, S.
    Zhang, Y.
    Chu, Y.
    Gupta, P.
    Li, Y.
    [J]. VALUE IN HEALTH, 2018, 21 : S62 - S62
  • [8] Practical application of dabigatran etexilate for stroke prevention in patients with atrial fibrillation
    Kosmacheva, E. D.
    Kanorskiy, S. G.
    Kastanayan, A. A.
    Haylo, N. V.
    Goltyapin, D. B.
    Lipnitskaya, E. A.
    Statsenko, M. E.
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2013, 9 (05) : 551 - 556
  • [9] COST EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN THE TURKISH HEALTH CARE SETTING
    Kececioglu, S.
    Ulus, P.
    Cukadar, F.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A373 - A373
  • [10] Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
    Sorensen, Sonja V.
    Kansal, Anuraag R.
    Connolly, Stuart
    Peng, Siyang
    Linnehan, John
    Bradley-Kennedy, Carole
    Plumb, Jonathan M.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2011, 105 (05) : 908 - 919
12345